Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
NCT05334368 · View on ClinicalTrials.gov ↗
Study Summary
This is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy. The study will recruit patients with a confirmed diagnosis of HES and who are on stable HES therapy for at least 4 weeks prior to randomization (Visit 2). Eligible participants must have uncontrolled HES with a history of repeated flare (≥2 flares in the previous 12 months) and blood eosinophil count of ≥1,000 cells/ microliter (μL) during Screening. Historical HES flares are defined as documented HES-related worsening of clinical symptoms or blood eosinophil counts requiring an escalation in therapy. Participants who meet the inclusion and exclusion criteria will be randomized in a 2:1 ratio to receive either depemokimab or placebo while continuing their SoC HES therapy.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Depemokimab
Study Locations (20)
Other
- GSK Investigational Site — Buenos Aires
- GSK Investigational Site — Florida
- GSK Investigational Site — La Plata
- GSK Investigational Site — Mar del Plata
- GSK Investigational Site — Quilmes
- GSK Investigational Site — Brussels
- GSK Investigational Site — Blumenau
Ohio
- GSK Investigational Site — Cincinnati
- GSK Investigational Site — Columbus
California
- GSK Investigational Site — San Diego
Georgia
- GSK Investigational Site — Atlanta
Massachusetts
- GSK Investigational Site — Boston
Michigan
- GSK Investigational Site — Southfield
Minnesota
- GSK Investigational Site — Rochester
New York
- GSK Investigational Site — Manhasset
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2022-09-06 |
| Est. Completion | 2028-12-19 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05334368
The ClinicalTrials.gov registry entry for NCT05334368 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 558 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Hypereosinophilic Syndrome appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05334368 reports 20 study locations spanning 13 distinct geographic areas — top geographies include Other, Ohio, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05334368 about?
NCT05334368 is a clinical study titled "Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial". This is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy. The study will recruit patients with a confirmed diagnosis of HES and who are on stable HES therapy for at leas...
What is the current status of trial NCT05334368?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 123 participants. The study started on 2022-09-06. Estimated completion is 2028-12-19.
What conditions does trial NCT05334368 study?
This clinical trial studies the following conditions: Hypereosinophilic Syndrome. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05334368?
The interventions under investigation include: Placebo (OTHER), Depemokimab (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05334368?
This trial is sponsored by GlaxoSmithKline, which has 558 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05334368 being conducted?
This trial has 20 study locations across California, Georgia, Massachusetts, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.